Maribavir: a novel antiviral agent with activity against cytomegalovirus
- PMID: 18698013
- DOI: 10.1345/aph.1L065
Maribavir: a novel antiviral agent with activity against cytomegalovirus
Abstract
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of maribavir, a novel antiviral agent in the benzimidazole drug class.
Data sources: Articles were identified through searches of MEDLINE (January 1998-July 2008). Abstracts from recent scientific meetings and the manufacturer were also included.
Study selection and data extraction: All English-language in vitro and in vivo studies and abstracts evaluating maribavir were reviewed and considered for inclusion. All human studies were included.
Data synthesis: Maribavir has significant activity against both human cytomegalovirus (CMV) and Epstein-Barr virus, but not other herpesviruses. Unlike ganciclovir, which needs to be phosphorylated by UL 97 kinase to become an active inhibitor of DNA polymerase, maribavir directly inhibits UL 97 kinase. UL 97 kinase is an early viral gene product involved in viral DNA elongation, DNA packaging, and egress or shedding of capsids from viral nuclei. Maribavir has also been found to be effective against ganciclovir-resistant CMV strains. Maribavir differs from current CMV antiviral agents in its adverse event profile. Maribavir is not associated with nephrotoxicity or hematologic toxicities, but has been associated with taste disturbances. In February 2007, maribavir was granted Food and Drug Administration orphan drug status for prevention of CMV viremia and diseases in at-risk populations. Maribavir Phase 2 trials in stem-cell transplant recipients have been completed, and there are ongoing Phase 3 trials in stem-cell and organ transplant recipients.
Conclusions: Maribavir may be an option for treatment of ganciclovir-resistant CMV infections. Its bioavailability is greater than that of oral ganciclovir, but less than that of valganciclovir. No differences in pharmacokinetics were seen in renally impaired patients, although dialysis-dependent patients were not evaluated. Maribavir is not associated with hematologic toxicities; however, the high prevalence of taste disturbances may limit its tolerability.
Similar articles
-
Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients.Transpl Infect Dis. 2010 Dec;12(6):489-96. doi: 10.1111/j.1399-3062.2010.00550.x. Transpl Infect Dis. 2010. PMID: 20682012
-
Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263.Drugs R D. 2007;8(3):188-92. doi: 10.2165/00126839-200708030-00006. Drugs R D. 2007. PMID: 17472414 Review.
-
Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with cytomegalovirus infection.J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):887-904. doi: 10.1007/s10928-024-09939-2. Epub 2024 Sep 27. J Pharmacokinet Pharmacodyn. 2024. PMID: 39333337 Free PMC article. Clinical Trial.
-
Maribavir (ViroPharma).Curr Opin Investig Drugs. 2004 Aug;5(8):898-906. Curr Opin Investig Drugs. 2004. PMID: 15600248 Review.
-
Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.Clin Infect Dis. 2019 Apr 8;68(8):1255-1264. doi: 10.1093/cid/ciy706. Clin Infect Dis. 2019. PMID: 30329038 Free PMC article. Clinical Trial.
Cited by
-
Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase.Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16823-8. doi: 10.1073/pnas.0901521106. Epub 2009 Sep 15. Proc Natl Acad Sci U S A. 2009. PMID: 19805380 Free PMC article.
-
Viral serine/threonine protein kinases.J Virol. 2011 Feb;85(3):1158-73. doi: 10.1128/JVI.01369-10. Epub 2010 Nov 17. J Virol. 2011. PMID: 21084474 Free PMC article. Review.
-
Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy.Int J Mol Sci. 2019 May 30;20(11):2666. doi: 10.3390/ijms20112666. Int J Mol Sci. 2019. PMID: 31151230 Free PMC article. Review.
-
Regulation of the retinoblastoma proteins by the human herpesviruses.Cell Div. 2009 Jan 15;4:1. doi: 10.1186/1747-1028-4-1. Cell Div. 2009. PMID: 19146698 Free PMC article.
-
Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.J Virol. 2009 Dec;83(23):12108-17. doi: 10.1128/JVI.01575-09. Epub 2009 Sep 16. J Virol. 2009. PMID: 19759127 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical